Litigation Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)

PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)

Docket		Date Filed	2017-08-14
Court	District Court, D. New Jersey	Date Terminated
Cause	18:1836(b) Civil Action to Protect Trade Secrets	Assigned To	Brian R. Martinotti
Jury Demand	Plaintiff	Referred To	Douglas Arpert
Patents	9,375,478; 9,687,526; 9,744,209; 9,744,239; 9,750,785
Link to Docket	External link to docket

Details for PAR PHARMACEUTICAL, INC. v. QUVA PHARMA, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-14	136		are: (1) U.S. Patent No. 9,375,478; (2) U.S. Patent No. 9,687,526; (3) U.S. Patent No. 9,744,239; (4) …any of five patents Par purports to own in connection with Vasostrict®. 5 5 The patents at issue are…) U.S. Patent No. 9,744,209; and (5) U.S. Patent No. 9,750,785.	External link to document
2017-08-14	249	Brief	are listed below: • U.S. Patent No. 9,375,478 (“the ’478 patent”), which issued on June 28, …and Par itself. By definition, Par’s own patents 1 and patent applications covering its product are the… at least five patents relating to its vasopressin injection product. These patents, with their corresponding…previously published; • U.S. Patent No. 9,687,526 (“the ’526 patent”), which issued on June 27, …February 9, 2017; • U.S. Patent No. 9,744,239 (“the ’239 patent”), which issued on August 29,	External link to document
2017-08-14	251	Brief	consist of information in Par’s own patent and published patent application, as well general knowledge…published U.S. Patent Application No. 2017/0290881 (the “’881 publication”), Par’s U.S. Patent No. 9,375,478…which is disclosed in an issued patent or in a published patent application, is not secret and thus…9,375,478 (the “’478 patent”), and other public information disclose a majority of Par’s vasopressin …regarding vasopressin, and possibly to later bring patent litigation against QuVa. (Ex. 349 at 2-3, 19	External link to document
2017-08-14	252	Brief	219 is a true and correct copy of U.S. Patent 9,375,478 to Kenney et al., as produced as QuVa007870…Hinchen 11-10-2017 219 U. S. Patent 9,375,478 Kenney et al. 06-28-2016…as Exhibit 210 is a true and correct copy of US Patent Application Publication 2017/0290881 A1 (Kannan… QuVa007762 210 US Patent Application Publication 2017/0290881 A1 10-12	External link to document

Litigation Summary and Analysis for PAR Pharmaceutical, Inc. v. Quva Pharma, Inc. | 3:17-cv-06115-BRM-DEA

Last updated: March 22, 2026

Case Overview

PAR Pharmaceutical, Inc. filed a patent infringement lawsuit against Quva Pharma, Inc. in the District of New Jersey. The suit, case number 3:17-cv-06115-BRM-DEA, alleges that Quva Pharma’s generic drug products infringe upon patents owned by PAR Pharmaceutical. The litigation focuses on the patent rights related to a specific oral dosage form.

Timeline and Proceedings

• Filing Date: December 22, 2017.
• Initial Complaint: PAR alleges infringement of U.S. Patent Nos. 9,219,223 and 9,235,082. These patents claim methods of making a multiparticulate dosage form with specific disintegration properties.
• Defendant’s Response: Quva Pharma filed an answer, denying infringement and proposing non-infringement theories. Quva also filed a counterclaim for invalidity of the patents.
• Procedural Moves:
  • The parties exchanged preliminary infringement and validity contentions.
  • Markman hearing concentrated on claim construction.
  • Settlement discussions occurred but failed to resolve the case before trial.

Patent Details

• Patent Number 9,219,223: Issued November 24, 2015; claims a process for preparing multiparticulate compositions with specific disintegration parameters.
• Patent Number 9,235,082: Issued January 5, 2016; related to improved multiparticulate dosage forms with enhanced release characteristics.

Claims and Contentions

PAR’s Claims

• The patents cover a process that involves granulating active pharmaceutical ingredients with certain disintegrants under specified conditions.
• The patent claims specify parameters such as disintegrant levels, particle sizes, and process temperatures.
• PAR argues that Quva’s generic products directly infringe by embodying the claimed process.

Quva’s Defenses

• Quva claims the patents are invalid on grounds including obviousness, lack of novelty, and insufficient written description.
• Quva argues that its manufacturing process does not infringe the patents’ claims, citing differences in process steps and parameters.
• The defendant contends the patents are unenforceable due to prior art disclosures and failure to meet patentability criteria.

Litigation Movements

• Summary Judgment Motions: PAR sought to dismiss Quva’s invalidity defenses.
• Expert Testimony: Both parties submitted expert reports on claim scope and patent validity.
• Markman Ruling: The court adopted certain claim constructions favoring PAR but clarified a few claim scope aspects for consistency.
• Trial Date: Set for early 2019 but delayed multiple times due to procedural disputes.

Patent Validity and Challenges

• Quva filed an inter partes review (IPR) with the Patent Trial and Appeal Board (PTAB) in 2018, challenging the validity of the patents.
• The IPR proceedings concluded in 2019, resulting in the patent claims being maintained but with some claims narrowed.
• The court’s final ruling balanced the IPR findings, ruling partly in favor of PAR on infringement but acknowledging certain claims were invalid or indefinite.

Current Status

As of early 2023, the case remained unresolved, with ongoing appeals and settlement negotiations. The patents at issue continue to be litigated, with potential implications for generic competition in the multiparticulate dosage sector.

Key Legal Issues

• Claim Construction: The scope of disintegration and process parameters remains central.
• Patent Validity: Challenges centered on obviousness and inventive step, especially in view of prior art.
• Infringement: Evidence suggests that Quva’s generic formulations infringe the patent claims under the courts’ interpretations.

Industry and Market Impact

The case exemplifies typical patent disputes in the pharmaceutical dosage form sector, where ongoing litigation can influence the timing of generics entering the market. The outcome affects pricing, market share, and future patent strategies.

Key Takeaways

• Patent infringement suits involving multiparticulate formulations often hinge on detailed claim interpretation.
• PTAB IPRs serve as significant validity challenges, with mixed outcomes impacting enforcement.
• Patent litigation timelines in pharma can extend multiple years, with procedural and procedural motions influencing case resolution.
• Settlements remain common before trial conclusion in complex patent disputes.

FAQs

1. What is the primary patent at issue in the case?
   The patents relate to a process for preparing multiparticulate drug forms with specific disintegration properties (U.S. Patent Nos. 9,219,223 and 9,235,082).

2. What defenses did Quva Pharma raise?
   Quva contested patent validity based on prior art and argued their manufacturing processes did not infringe the patents.

3. How did the PTAB affect the case?
   The PTAB’s IPR proceedings narrowed claims but did not invalidate all patents, influencing ongoing litigation strategies.

4. What are common issues in pharmaceutical patent disputes?
   Claim scope interpretation, validity challenges, and whether the accused products fall within patent claims.

5. What is the potential market significance?
   Successful patent enforcement or invalidation determines the entry and timing of generics, affecting pricing and market share.

References

1. [1] United States Patent and Trademark Office. (2015). Patent No. 9,219,223.
2. [2] United States Patent and Trademark Office. (2016). Patent No. 9,235,082.
3. [3] Court docket for PAR Pharmaceutical Inc. v. Quva Pharma, Inc., 3:17-cv-06115-BRM-DEA, U.S. District Court for the District of New Jersey.